CSIMarket
 
Allergan plc  (AGN)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 332
 Employees 10,500
 Revenues (TTM) (Millions $) 16,096
 Net Income (TTM) (Millions $) -2,479
 Cash Flow (TTM) (Millions $) 211
 Capital Exp. (TTM) (Millions $) 479

Allergan Plc
Allergan plc is a global pharmaceutical company that was founded in 1950 in California, USA. It specializes in developing, manufacturing, and marketing branded pharmaceuticals, biologics, medical devices, and over-the-counter products for the treatment of neurological, ophthalmologic, medical aesthetics, and gastroenterological conditions.

Allergan is based in Dublin, Ireland, and operates in around 100 countries worldwide. It employs more than 18,000 people across its research and development, manufacturing, and commercial operations. In 2020, the company reported annual revenue of $16.6 billion.

The company's portfolio of products includes Botox, which is used for cosmetic and medical purposes, as well as treatments for eye diseases, migraines, irritable bowel syndrome, and other conditions. Some of Allergan's leading brands include Juvederm, Coolsculpting, Latisse, Restasis, and Ozurdex.

Allergan has a strong focus on research and development, investing heavily in clinical trials and innovation. The company has research facilities in the US, Europe, and Asia, and collaborates with other organizations and academic institutions to advance scientific discovery in its areas of focus.

In 2019, Allergan was acquired by AbbVie, a research-based pharmaceutical company based in North Chicago, Illinois, in a deal worth $63 billion. The acquisition positioned AbbVie as a leading pharmaceutical company with a diverse portfolio of medicines and products, including Allergan's portfolio of medical aesthetics and eye care products.

Overall, Allergan is a leading global pharmaceutical company with a strong reputation for innovation and a diverse portfolio of products that help improve the lives of patients.


   Company Address: Clonshaugh Business and Technology Park Dublin 0
   Company Phone Number: 261-7000   Stock Exchange / Ticker: NYSE AGN
   


Customers Net Income grew by AGN's Customers Net Profit Margin fell to

6.01 %

4.64 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AGRX   -24.37%    
JNJ   -3.67%    
MRK   -0.99%    
PFE   -1.04%    
TEVA        0.6% 
AMGN   -2.04%    
• View Complete Report
   



Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.

Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc Faces Stock Plunge and Financial Contraction in Fiscal Fourth Quarter of 2023

Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average.
The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.

Soligenix Inc

Soligenix Inc Narrows Fourth Quarter Shortfall 2.

As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year.
In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance.
Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.

Eterna Therapeutics Inc

Eterna Therapeutics Inc Reports Revenue of $0.017 Million in Q4 2023 Financial Results

In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products.
Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.






 

Allergan Plc's Segments
 
Eye Care Pharmaceuticals
 Segment     of total Revenue
Skin Care
 Segment     of total Revenue
BOTOX/Neuromuscular
 Segment     of total Revenue
Total Specialty Pharmaceuticals
 Segment     of total Revenue
Alphagan P & Alphagan
 Segment     of total Revenue
Lumigan
 Segment     of total Revenue
Restasis
 Segment     of total Revenue
Latisse
 Segment     of total Revenue
Breast Aesthetics
 Segment     of total Revenue
Facial Aesthetics
 Segment     of total Revenue
Total Medical Devices
 Segment     of total Revenue
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Allergan Plc does not provide revenue guidance.

Earnings Outlook
Allergan plc does not provide earnings estimates.

 
Geographic Revenue Dispersion
United States
Europe
Asia Pacific
Latin America
Other




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com